Physician profile
Steven Christopher Mitchell
NPI 1972500460
$2,853.52
in general payments reported to CMS, 2019-2025
22 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $380 · 2021: $500 · 2022: $351 · 2023: $296 · 2024: $453 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $701.41 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $475.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $380.28 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $174.23 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $166.34 | 2019-2023 | |
| Amarin Pharma, INC. | $130.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $95.61 | 2019-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $93.61 | 2022-2024 | Verquvo, Belsomra, Gardasil |
| Dexcom, INC. | $93.25 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.56 | 2019-2021 | |
| Amgen INC. | $71.11 | 2019-2022 | |
| Exact Sciences Corporation | $61.92 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.84 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $58.71 | 2019-2023 | Invega Sustenna |
| Abbvie INC. | $57.56 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $44.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.21 | 2025 | |
| Mylan Specialty L.P. | $23.62 | 2021 | |
| Inspire Medical Systems, INC. | $15.21 | 2025 | Inspire |
| Allergan, INC. | $13.03 | 2019 | |
| Esperion Therapeutics, INC. | $12.61 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.